The Central Drugs Standard Control Organisation (CDSCO) has received a strategic recommendation submitted by the Indian Pharmacopeia Commission’s (IPCs) review panel. Based on the adverse drug reaction (ADR) generated by ADR centres, these reports were submitted. One of the recommendations is that CDSCO should guide all manufacturers to clearly mention the possible side effects of the drug said Dr. Kalaiselvan. READ ALSO: Entry strategies for foreign investors in India.
“Considering the seriousness of this matter, the panel has suggested the DCGI to take the above requisite steps for public safety. Apart from carbamazepine, IPC has also submitted recommendation to the Centre on two anti cancer drugs sunitinib and pazopanib as well. Based on the panels observation it has recommended the CDSCO to closely monitor these two drugs as there have been several incidents of ADRs reported from the use of these drugs,” he stressed.
He further added, “After intensive study and analysis of ADR reports from around 100 ADR centres across the country the recommendation has been submitted to the CDSCO. Due to the seriousness, the panel wants CDSCO to take steps for the safety of patients. CDSCO (The Central Drugs Standard Control Organisation) is the Indian regulatory body of India who is responsible for the regulation of drugs, medical devices and cosmetics in India. READ ALSO: Achievements of the Indian regulatory body CDSCO.
Other News
Imports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read More
ErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More
TUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More
TGA Supports MHRA’s New Regulations
The TGA made a commitment to support the MHRA‘s new Regulations worldwide recognition framework for pharmaceuticals. Following the UK’s exit from the European Union, a new international recognition framework for medicines has been developed specifically […]
Read More
